Table 1. Mice used in pre- and post-treatment experiments.

Numbers of adult CD1 mice
Pre-treatment			Post-treatment
Groups	IHC	WB	Groups	IHC/FJC	WB	EB	EEG
Vehicle	12	8	Pilocarpine	24	45	39	29
IVIg	13	7	SE mice	16	19	20	18
Vehicle SE	7	5	Vehicle	8	9	11	5
				(21.8 ± 1.6)	(21.6 ± 2.2)	(20.6 ± 1.8)	(21.5 ± 2.8)
IVIg SE	4	4	IVIg	8	10	9	7
				(21.0 ± 2.5)	(20.7 ± 1.3)	(21.9 ± 3.4)	(24.2 ± 3.1)

In pre-treatment experiments, mice were randomly allocated to receive vehicle or IVIg before administration of pilocarpine. Animals developing SE were used for immunohistochemistry (IHC), Fluoro Jade C staining (FJC) and western blotting (WB) studies, as shown in the bottom two rows.

In post-treatment experiments, mice developing SE were randomly allocated to receive vehicle or IVIg. The number of animals receiving pilocarpine (Post-treatment, Row 1), the number developing SE (Row 2) are shown. The number of animals receiving vehicle or IVIg used for IHC, WB, Evans blue staining (EB) and electroencephalography (EEG) are shown in Rows 3 and 4. The numbers in brackets are the seizure scores of each group (modified Racine scale, mean ± standard error of the mean, no significant difference between SE vehicle and SE IVIg groups, unpaired t-test). Fewer animals underwent EEG recording than were randomised due to the death of 3 vehicle-treated and 3 IVIg-treated animals before EEG recording.